Cassava Sci Rg

Cassava Sciences, Inc. is a clinical‑stage biopharma developing neurodegenerative disease therapeutics. Its lead drug, simufilam, completed Phase‑2 trials; SavaDx offers a blood‑based biomarker to diagnose Alzheimer’s early.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 30
HQ: Austin

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
SAVA	Cassava Sci Rg Cap: 0.1B	EQUITY	NCM	USD	US14817C1071	Active	📈